PlatinumRx

PlatinumRx

How to order medicine

Contact usLogin
Diabetes Care
Type 2 Diabetes
Diabetes Medicines
Dietary Care
Insulin Injection
Test Strips
Sugar Substitutes
Health Conditions
Heart Care
Pain Relief
Digestive Care
Eye Care
Kidney Care
Liver Care
Respiratory Care
Stomach Care
Healthcare Devices
Miscellaneous
Personal Care
Skin Care
Sexual Wellness
Cough And Cold
Hair Care
Bone And Joint
Baby And Mom Care
Skin and Body Soap
Miscellaneous
Vitamins And Supplements
Calcium And Minerals
Vitamin A To Z
Minerals Supplements
Gut Health And Digestive Support
Vitamin B12 And Complex
Protein Supplements
Omega And Fish Oil
Baby And Mom Care
Vitamins And Bone Health Supplements
Supplement Powder
Nutritional Support For Hair
Heart And Circulatory Wellness
Miscellaneous
Health Resources
All Salts
All Diseases
All Medicines
All Health Products
Blogs

Casirivimab + Imdevimab

Uses

Casirivimab and Imdevimab are used in the treatment of Coronavirus disease (COVID-19).

How it Works

How Casirivimab and Imdevimab work Casirivimab and Imdevimab are a combination of two human immunoglobulin G-1 (IgG1) neutralizing monoclonal antibodies that bind at different sites on the spike protein of SARS-CoV-2, the virus that causes COVID-19. This unique binding mechanism, developed using recombinant DNA technology, is effective against both existing and emerging variants, preventing the virus from attaching to human cell receptors.

Side Effects

Common side effects of Casirivimab and Imdevimab include injection site reactions such as pain, swelling, and redness.

Expert Advice

  • Casirivimab + Imdevimab, a monoclonal antibody cocktail therapy, is used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents aged 12 years and older, who weigh at least 40 kg.
  • The use of monoclonal antibodies is not indicated in severe hospitalized cases of COVID-19 or in patients requiring oxygen therapy.
  • Even after treatment, continue to practice COVID-appropriate behaviors, such as:
    • Wearing a mask
    • Social distancing
    • Avoiding sharing personal items
    • Frequent handwashing
  • Before starting this antibody cocktail therapy, inform your doctor of any underlying medical conditions, including:
    • Diabetes
    • Heart disease
    • High blood pressure
    • Kidney disease
    • Asthma
  • Patients should be monitored during treatment and for at least one hour after the completion of the infusion.
  • Severe allergic reactions may occur during and after the use of monoclonal antibodies. Inform your doctor or nurse immediately if you experience:
    • Shortness of breath
    • Rapid or slow heart rate
    • Chest pain
    • Swelling of the face or lips
    • Excessive sweating

Other Combinations

Frequently asked questions

A monoclonal antibody cocktail is a mixture of different monoclonal antibodies that are usually available separately but are combined for therapeutic use.
Casirivimab+Imdevimab is administered intravenously or subcutaneously by a healthcare professional in a hospital setting to treat mild to moderate COVID-19 symptoms. It should not be given intramuscularly.
Individuals over 60 years old, those who are obese, have lung or kidney-related comorbidities, or have weakened immune systems, such as cancer patients, are at increased risk for severe COVID-19.
Individuals who are hospitalized, require oxygen therapy, or have pre-existing conditions leading to oxygen treatment should not use monoclonal antibodies. Additionally, those allergic to Casirivimab or Imdevimab or any components of the treatment should refrain from using it.
Monoclonal antibodies are engineered to bind to the spike protein of SARS-CoV-2, preventing the virus from entering human cells and thereby potentially halting disease progression. They may be effective in treating mild symptoms early in the infection.
Monoclonal antibody therapy for COVID-19 should be administered following an early diagnosis in patients aged 12 and older who weigh at least 40 kg. It is also recommended for individuals at high risk for severe infection, such as those over 60 years old or with comorbid conditions like diabetes or hypertension.
Monoclonal antibodies are specialized proteins that replicate the immune system's ability to combat harmful pathogens. Casirivimab and Imdevimab are monoclonal antibodies included in Casirivimab+Imdevimab, which provide protection against SARS-CoV-2, the virus responsible for COVID-19.
Yes, individuals with high blood pressure or diabetes can take Casirivimab+Imdevimab if prescribed. Current data suggests that the benefits of monoclonal antibody therapy outweigh potential risks.
;